Pure Global
NCT03500562

Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)

Daclatasvir-Based Therapy Safety Surveillance in Chinese Patients With Chronic Hepatitis C
Bristol-Myers Squibb·ClinicalTrials.govTerminated
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Hepatitis C
Study type
Observational
Sponsor & location
Primary sponsor
Bristol-Myers Squibb
Location
Beijing,Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
May 08, 2018
End date
Mar 29, 2019
Enrollment
3 participants
Primary outcome

Number of adverse events (AEs),Number of serious adverse events (SAEs)

Summary

Study is a non-interventional, prospective, multicenter post marketing surveillance study to
 determine the safety of daclatasvir based therapy

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic viral hepatitisOther chronic viral hepatitisChronic hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03500562
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03500562 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb and is currently Terminated. The study focuses on Chronic Hepatitis C. Target enrollment is 3 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.